Sodium-potassium ATPase alpha subunit (Na⁺/K⁺-ATPase α subunit (often ATP1A1, ATP1A2, ATP1A3, ATP1A4 for specific isoforms))

The sodium-potassium ATPase alpha subunit is the catalytic component of the Na⁺/K⁺-ATPase, a membrane-bound enzyme that maintains crucial sodium and potassium gradients across the plasma membrane of most animal cells[3][5][8][9]. This P-type ATPase actively exports three sodium ions from and imports two potassium ions into the cell with every hydrolyzed ATP molecule, an energy-consuming process essential for electrical excitability, secondary nutrient transport, and cellular homeostasis[1][2][5]. The alpha subunit forms a complex with a regulatory beta subunit and an FXYD accessory protein, with distinct alpha isoforms expressed in different tissues (ATP1A1 in most tissues, ATP1A2 in heart/brain/muscle, ATP1A3 mainly in neurons, ATP1A4 in testis)[5][8]. Its role as a drug target is established for cardiac glycosides in heart failure and arrhythmias; recent research implicates the alpha subunit in cancer, neurological, and metabolic diseases, with both inhibitory and regulatory pathways under investigation[2][4][6]. Mutations in genes encoding different alpha isoforms cause rare but severe neurological disorders, underscoring its broad physiological importance[5][8].

Other names

Sodium pump alpha subunitNa⁺/K⁺-ATPase alpha subunitNa⁺-K⁺-ATPase alpha subunitATP1A1 (for alpha1)ATP1A2 (alpha2)ATP1A3 (alpha3)ATP1A4 (alpha4)Sodium and potassium-transporting ATPase alpha chainSodium-potassium pump alpha subunit

Inhibition of Na⁺/K⁺-ATPase by cardiac glycosides increases intracellular sodium, which reduces calcium efflux (via the sodium/calcium exchanger), leading to enhanced cardiac contractility[6]. Inhibition causes altered cell signaling, apoptosis, and cell-cycle arrest in certain cancer cells[4]. Modulation of pump activity alters cellular ion homeostasis and signal transduction, impacting processes like cell proliferation and volume regulation[2][5].